Cue Biopharma Q2 2024 GAAP EPS $(0.20) Beats $(0.24) Estimate, Sales $2.658M Beat $1.293M Estimate

Cue Biopharma (NASDAQ: CUE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) by 16.67 percent. The company reported quarterly sales of $2.658 million which beat the analyst consensus estimate of $1.293 million by 105.61 percent. This is a 92.33 percent increase over sales of $1.382 million the same period last year.